Home
About
Overview
Sharing Data
ORCID
Help
History (11)
The prevalence and causes of visual impairment in indigenous Australians within central Australia: the Central Australian Ocular Health Study.
Randomized phase II trial designs with biomarkers.
When communities collide.
A prospective multi-site registry of real-world experience of catheter ablation for treatment of symptomatic paroxysmal and persistent atrial fibrillation (Real-AF): design and objectives.
Rapamycin in Cerebral Cavernous Malformations: What Doses to Test in Mice and Humans.
See All 11 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Rapamycin in Cerebral Cavernous Malformations: What Doses to Test in Mice and Humans.
Rapamycin in Cerebral Cavernous Malformations: What Doses to Test in Mice and Humans. ACS Pharmacol Transl Sci. 2022 May 13; 5(5):266-277.
View in:
PubMed
authors with profiles
Issam Awad
Robert Shenkar
Romuald Girard